Azienda Ospedaliera Ordine Mauriziano Di Torino
Verified site
Turin, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Endometrial cancer is a disease that starts in the lining of the uterus. In some patients the tumor is classified as mismatch repair proficient (MMRp), meaning the cells’ normal DNA‑repair system is still working. The study focuses on people whose disease is advanced or has come back after earlier treatment.
The investigational medicine being tested is mocertatug rezetecan. It is given together with a doctor‑chosen form of immune checkpoint inhibition, either the drug dostarlimab or the drug pembrolizumab. These immunotherapy medicines help the body’s immune system recognize and attack cancer cells. The trial compares this combination with using the immunotherapy alone.
The purpose is to determine whether adding the new drug helps keep the cancer under control for a longer time. Participants receive the assigned treatment by intravenous infusion (medicine delivered through a vein) and have regular check‑ups, scans, and laboratory tests to monitor the cancer and overall health. The study continues until the disease progresses, the treatment is stopped, or the planned follow‑up period ends.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
15 criteria
27 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an immune‑checkpoint inhibitor that helps the body’s immune system see and attack cancer cells. In this study it is given by intravenous infusion as one of the standard immunotherapy options.
is another immune‑checkpoint inhibitor that works in a similar way to pembrolizumab, releasing the “brakes” on the immune system so it can target cancer. It is also administered by intravenous infusion as a standard immunotherapy choice.
is an experimental drug being evaluated in the trial. It comes as a powder that is mixed with liquid to create a solution for infusion. The study is testing whether this new agent can improve outcomes when used with other treatments.
(often called Mo‑Rez) is the investigational therapy being studied in combination with the immune‑checkpoint inhibitors. It is given by intravenous infusion and is intended to work together with the immunotherapy drugs to help keep the cancer from returning after initial treatment.
This medication is given as an intravenous infusion, meaning it is slowly dripped into a vein. It is an approved drug used in many cancers, including certain endometrial cancers, and is described in many medical studies. It works by attaching to a protein called PD‑1 on immune cells, which helps the immune system see and attack cancer cells. It belongs to the class of medicines known as immune checkpoint inhibitors.
This drug is also given by intravenous infusion, where the solution is injected slowly into a vein. It is an approved treatment for several cancers, such as endometrial cancer, and is widely reported in the medical literature. It blocks the PD‑1 protein on immune cells, allowing the body’s defenses to recognize and fight tumor cells. It is classified as an immune checkpoint inhibitor.
This product is supplied as a powder that is mixed with liquid and then given by intravenous infusion. It is still experimental and is being studied in clinical trials, so it is not yet approved for regular medical use. The exact way it works is still being researched, but it is intended to help the immune system target cancer cells. It is considered an investigational biologic agent.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.